S E T T I N G : Alcohol use increases the risk of multidrugresistant tuberculosis (MDR-
Heavy alcohol use is associated with an increased risk of tuberculosis infection and active disease. [2] [3] Alcohol use has been documented to increase the risk of certain adverse events during TB treatment, including hepatotoxicity, [4] [5] neuropathy, 6 and psychosis, 7 and may potentially increase the risk of additional adverse events (i.e., electrolyte disturbance, depression, seizure and gastric intolerance) due to overlapping toxicities. 8 Finally, alcohol use disorders are associated with worse treatment outcomes. The mechanisms by which alcohol contributes to unfavourable outcomes are both biological and social in nature, including death from alcohol-related causes and default or failure due to non-adherence and adverse events. [9] [10] [11] [12] [13] [14] [15] [16] Multidrug-resistant tuberculosis (MDR-TB) is defi ned as Mycobacterium tuberculosis bacilli resistant to at least isoniazid and rifampicin. Treatment for MDR-TB is more diffi cult, costly and yields worse outcomes than for drug-susceptible TB. 17, 18 Alcohol use disorders (AUDs) increase the diffi culty of MDR-TB management and control. Alcohol use is associated with a greater risk of MDR-TB and extensively drug-resistant TB (XDR-TB) in several settings, 9, 19, 20 and worse outcomes among MDR-TB cohorts. 21, 22 Challenges in MDR-TB treatment due to alcohol use are particularly salient in settings with 'converging epidemics' of MDR-TB and AUDs. As the only country that ranks on both the World Health Organization's (WHO's) list of high TB burden countries and the 'top ten' countries with the highest per capita alcohol consumption, the Russian Federation is an illustrative example from this perspective. 1, 23 In 2011, furthermore, the WHO estimated that 18% of new TB and 46% of recurrent TB cases in the Russian Federation were MDR-TB cases. 24 According to the 23 Rehm et al. have estimated that the proportion of TB in Russia attributable to alcohol exposure ranges from 37% to 54% in men and from 9% to 17% in women. 25 In Russia and other settings, providers are faced with the dilemma of whether to offer MDR-TB treatment to individuals with AUDs given the potentially elevated risk of adverse events, poor adherence and unfavourable outcomes among this 'diffi cult to manage' population. Providers who do treat such patients must weigh decisions regarding the choice of drug and toxicity management in this population, with minimal insight available from the published literature. Responding to this knowledge gap, we sought to describe the frequency of second-line drug treatment related adverse events among individuals who drank alcohol during MDR-TB treatment in Tomsk, Russia, compared with those who did not drink alcohol, and to explore the impact of these adverse events on treatment outcomes.
STUDY POPULATION AND METHODS

Study setting and treatment programme
Tomsk oblast is located in Western Siberia, Russian Federation. About 50% of its 1 035 000 population live in remote rural areas. As in the rest of the former Soviet Union, MDR-TB is a signifi cant problem in the region. Between 1998 and 2002, rates of MDR-TB rose from 6.5% to 16% for new cases, and from 26.7% to 43.6% among retreatment cases, 26 despite the introduction and expansion of WHO's DOTS strategy. In 2000, the prison and civilian TB programmes in Tomsk incorporated MDR-TB treatment for patients with either documented MDR-TB or probable MDR-TB (i.e., based on history of treatment failure). The programme was scaled up throughout the oblast from 2000 to 2004, and infl uenced national norms for the treatment of MDR-TB in Russia and other countries of the former Soviet Union.
Procedures for bacteriology and drug susceptibility testing (DST) are described elsewhere. 22, 27 In brief, prior to the start of treatment, smear microscopy and culture on Löwenstein-Jensen media were performed at local laboratories. DST was initially performed by the Massachusetts State Laboratory Institute, and later transferred to the Tomsk reference laboratory.
Patient treatment and adverse reaction management have been described elsewhere. 22, [27] [28] Regimens were individualised based on drug resistance data and prior treatment history, with efforts to include at least fi ve drugs to which the infecting isolate was confi rmed or likely to be susceptible. All treatment was provided under directly observed therapy. Adverse reactions were aggressively managed at no cost to the patient. All TB physicians were trained using standardised protocols for the diagnosis and management of adverse events associated with anti-tuberculosis drugs. Routine laboratory monitoring of liver function tests, creatinine and potassium was conducted monthly, and thyroid stimulating hormone monitoring was conducted bi-monthly, with pre-established thresholds for laboratory-defi ned adverse events. Adverse events not defi ned by laboratory data were determined on a clinical basis.
Patients
Between 10 September 2000 and 1 November 2004, 636 patients from both the civilian and incarcerated population were consecutively enrolled in the programme. Of these, 608 had documentation of MDR-TB at baseline. To assess the impact of alcohol use during treatment, analysis was limited to the 407 patients with confi rmed MDR-TB who started treatment in the civilian sector.
Ethical considerations
The study was reviewed and approved by the Institutional Review Boards of Harvard School of Public Health (Boston, MA, USA) and the Siberian State Medical University in Tomsk, Russia.
Data collection and analysis
Clinical data were captured on forms prospectively completed by TB providers, abstracted through retrospective chart review and entered into an electronic medical record, which used a Microsoft SQL server 2000 (Microsoft Corporation, Seattle, WA, USA). Chart reviews were supplemented by laboratory and TB registry data from Tomsk oblast.
Alcohol use during treatment was defi ned as a physician documenting alcohol consumption and/or inebriation during treatment in the patient's chart. A baseline AUD was defi ned as documentation of a diagnosis of alcoholism at intake by a physician or mental health provider (e.g., psychiatrist, psychologist, addiction specialist). Body mass index (BMI) was calculated as kg/m 2 , and was considered low if <18.5 in females or <20 in males.
XDR-TB was defi ned as documented MDR-TB plus resistance to any second-line aminoglycoside or capreomycin, plus any fl uoroquinolone. 29 A patient was considered to be 'adherent' to treatment if he/she took ⩾80% of prescribed doses, as recorded on the treatment administration forms.
Defi nitions of specifi c adverse events are presented in Table 1 . We collected all relevant laboratory data, as well as clinically defi ned events as recorded by the treating physician. Treatment outcomes were defi ned as in Laserson et al. 30 A 'favourable' outcome was defi ned as cure or treatment completion. 'Poor' treatment outcomes included default, failure or death from any cause during MDR-TB treatment.
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Analyses were conducted using Stata version 11.1 (College Park, TX, USA). Continuous data were a ssessed for normality using a skewness-kurtosis test. Demographic data and specifi c adverse reactions were compared in 2×2 tables using Student's t-test or Wilcoxon rank sum tests, as appropriate, for continuous variables, and using Pearson's χ 2 or Fisher's exact test for categorical variables. Univariable and multivariable logistic regression were conducted to assess factors associated with treatment outcomes. Variables included in univariable analysis were included based on existing literature and factors of prior signifi cance in an earlier version of this cohort. Variables significant at P = 0.1 were considered for inclusion in the multivariable analysis. A fi nal model was determined using likelihood ratio testing. Variables included in the multivariable analysis were assessed for interaction and effect modifi cation. Table 2 shows baseline demographic and clinical information for the cohort. Of 407 non-incarcerated civilian patients treated for documented MDR-TB, 253 (62%) used alcohol during treatment. Patients who used alcohol during treatment ('drinkers') were strikingly different from those who did not ('nondrinkers'). Drinkers were more likely to be male, older, unemployed, smokers, have a past history of incarceration and/or homelessness, and have the following baseline characteristics: bilateral and cavitary disease and a diagnosis of alcoholism (P for all characteristics < 0.01).
RESULTS
Clinical management
Baseline drug regimens for drinkers and non-drinkers were similar (Table 3) , as were rates of laboratory monitoring per protocol (data not shown). At least one serum potassium value of <3 mEq/l Hypothyroidism At least one measure of TSH >10.0 IU/ml TB = tuberculosis; ICD = International Classification of Diseases; AST = a spartate aminotransferase; ALT = alanine aminotransferase; ULN = upper limit of normal; TSH = thyroid-stimulating hormone. MDR-TB = multidrug-resistant tuberculosis; OFX = ofloxacin; CS = cycloserine; PAS = para-aminosalicylic acid; PZA = pyrazinamide; THA = thiamide; CM = capreomycin; KM = kanamycin; EMB = ethambutol; AMOX-CLAV = amoxicillinclavulanate; RFB = rifabutin; INH = isoniazid; MFX = moxifloxacin; AMK = amikacin.
Frequency and type of adverse events in drinkers vs. non-drinkers
The majority of the cohort (90.2%) had at least one documented adverse event during treatment. The total number of different adverse events experienced by each patient over the course of treatment ranged from zero to seven. The most frequent adverse events were gastrointestinal: of those who had an adverse event, approximately 78% experienced either nausea and vomiting or diarrhoea. Other frequently occurring adverse events included arthralgia (44.2%) and hypokalaemia (38.3%). Table 4 provides a comparison of adverse events between drinkers and nondrinkers. Drinkers and non-drinkers did not significantly differ with respect to development or number of adverse events in general; 90.9% of drinkers vs. 88.9% of non-drinkers experienced an adverse event (P = 0.52); the mean number of different events was 2.7 for drinkers (standard deviation [SD] 1.6) and 2.8 for non-drinkers (SD 1.6, P = 0.4). There was no difference in time to presentation among drinkers vs. non-drinkers for all types of adverse events except diarrhoea, which occurred later among drinkers vs. non-drinkers (median 2.5 months vs. 1 month after treatment start, P = 0.002). Among adverse events diagnosed with laboratory data (nephrotoxicity, hepatotoxicity, hypokalaemia and hypothyroidism), the severity of each event at the time of presentation did not differ signifi cantly among drinkers vs. nondrinkers. Permanent interruptions of anti-tuberculosis drugs due to adverse events were generally uncommon. Overall, and for each type of reaction, the rate of drug discontinuation due to adverse events among drinkers vs. non-drinkers did not differ signifi cantly. Table 5 provides treatment characteristics for the cohort. Overall, 247/407 (61%) had favourable treatment outcomes. Alcohol use during treatment was negatively associated with favourable outcome (P < 0.001), and positively associated with death (P < 0.0001) and default (P < 0.05). As alcohol use was associated with non-adherence during treatment, we explored whether the adverse impact of drinking on treatment outcome could be mediated by nona dherence. Controlled for non-adherence, drinking was still negatively associated with favourable treatment outcome (adjusted odds ratio [OR] 0.38, 95% confi dence interval [CI] 0.23-0.61). We also explored whether there were differences in time to default based on alcohol use (n = 93 defaulters), and found a nonsignifi cant trend toward earlier default among drinkers vs. non-drinkers (mean [± SD] 230 ± 124 days vs. 248 ± 154 days, P = 0.77).
Treatment outcomes
We explored factors associated with poor treatment outcome, stratifi ed by alcohol use. Among drinkers, a diagnosis of alcoholism at baseline and severe TB (bilateral and cavitary disease at baseline) were associated with worse treatment outcomes ( Table 6) . Interruption of treatment due to side effects and adherence to at least 80% of prescribed doses were associated with favourable treatment outcomes in drinkers. In multivariable analysis, greater adherence (OR Table 4 Adverse events among individuals who drank alcohol vs. those who did not during MDR-TB treatment in Tomsk, Russian Federation (N = 407)
Characteristic n In non-drinkers, univariate analysis showed that male sex, smoking at baseline and a history of prior incarceration were associated with worse outcomes (Table 7) , and adherence to at least 80% of prescribed doses was associated with better outcomes. In multivariable analysis, a history of prior incarceration (OR 0.34, 95%CI 0.14-0.79), baseline history of smoking (OR 0.19, 95%CI 0.05-0.71) and treatment adherence (OR 4.27, 95%CI 1.06-17.11) were all significantly associated with treatment outcome.
DISCUSSION
In this non-incarcerated population of MDR-TB patients with high levels of alcohol use during treatment, alcohol use did not confer an increased risk of adverse events during MDR-TB treatment. Notably, despite the well-known effects of alcohol on the liver, alcohol use during treatment was not signifi cantly associated with development of hepatotoxicity. We tested this fi nding at elevations of both three and fi ve times the normal limits of transaminases, with no difference in fi ndings. Given that treatment regimens and frequency of laboratory monitoring did not differ signifi cantly among drinkers vs. non-drinkers, these data provide reassurance that individuals who drink alcohol during MDR-TB treatment can be managed using the same principles of regimen design, without necessarily incurring excess toxicity due to interactions or synergy between anti-tuberculosis drugs and alcohol consumption.
However, alcohol use during treatment was associated with poor treatment outcome, in large part due to increased rates of death and default. Non-adherence was associated with poor treatment outcome for both drinkers and non-drinkers. Recognition of this unsurprising factor led to the development of a programme to address those TB patients at risk for non-adherence in Tomsk. The 'Sputnik' programme, implemented in December 2006, provides intensive programmatic support to those most at risk of nonadherence and default, and has been very successful, with cure rates of 71% and mean adherence improving from 52% to over 80%. 31 Other characteristics associated with treatment outcome differed among those who did and did not consume alcohol during treatment. Cigarette use was associated with worse treatment outcomes in nondrinkers, but not in drinkers. Smoking is known to be associated with worse TB treatment outcomes in general; 32-34 however, we were only able to document this for the non-drinkers. A possible reason for this fi nding is that almost all of the drinkers were also smokers (96%); any additional burden of tobacco use would probably have been masked.
Interestingly, we found that treatment interruption due to an adverse event was associated with favourable treatment outcomes in drinkers. It is possible that greater attention was paid to individuals who developed adverse events, resulting in improved management and treatment outcome. An alternative explanation is that those who were followed more closely were subsequently more likely to have an adverse event identifi ed and appropriately managed by providers, resulting in improved outcomes.
This study provides some of the fi rst data on adverse events in a population with high rates of alcohol use. One major limitation of the study is the retrospective nature of the data collection. Alcohol use during treatment and alcoholism diagnosis were captured based on physician diagnosis and documentation. We were unable to assess amounts and frequency of alcohol use, or relate the chronology of drinking episodes with respect to adverse events. The Alcohol Use Disorders Identifi cation Test (AUDIT), which has been validated in this population, could provide an instrument to gauge degree of alcohol use; 35 future prospective studies may be able to capture some of these important nuances.
CONCLUSIONS
Alcohol use during treatment was not associated with increased risk or number of adverse events during MDR-TB treatment. High treatment adherence and development of an adverse event requiring treatment interruption were associated with favourable outcomes in alcohol users. Interventions to promote high treatment adherence and retention among drinkers, aggressive management of adverse events and integrated alcohol care within TB services 36, 37 could result in lessening the imbalance in favourable treatment outcomes for those who use alcohol. * Entered into main effects multivariable model. MDR-TB = multidrug-resistant tuberculosis; OR = odds ratio; CI = confidence interval; XDR-TB = extensively drug-resistant tuberculosis; AEs = adverse events.
